Combination of methotrexate and prednizone decreases circulating concentrations of interleukin 1β and interleukin 6 in patients with rheumatoid arthritis, poor correlation of cytokine suppression with clinical improvement

International Journal of Immunopathology and Pharmacology

Volumn 12, Issue 1, 1999, Pages 13-21

  Nowak, D ^a   Lewandowicz, J ^a   Dbkowska, B ^a   Marczak, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cytokines; Methotrexate; Prednizone; Rheumatoid arthritis; Thiobarbituric acid reactive substances

Indexed keywords

ACUTE PHASE PROTEIN; AZATHIOPRINE; CYTOKINE; GOLD; HYDROXYCHLOROQUINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; PENICILLAMINE; PIROXICAM; PREDNISONE; SALAZOSULFAPYRIDINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0032950912     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dolhain R.J.E.M., P.P. Tak, B.A.C. Dijkmans, P. De Kuiper, F.C. Breedveld and A.M.M. Miltenburg. 1998. Metotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br. J. Rheumatol. 37:502.
2. Leeuwen M.A., J. Westra, P.C. Limburg, P.L.C.M. Riel, and M.H. Rijswijk. 1995. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophIL activation in rheumatoid synovial fluid. Ann. Rheum. Dis. 54:33.
3. Madhok R., A. Crilly, J. Watson and H.A. Capell. 1993. Serum interleukin-6 levels in rheumatoid arthritis. Correlations with clinical and laboratory indicies of disease activity. Ann. Rheum. Dis. 52:232.
4. Dasgupta B., M. Corkill, B. Kirkham, T. Gibson and G. Panayi. 1992. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol. 19:22.
5. Straub R.H., U. Muller-Ladner, T. Lichtinger, J. Scholmerich, H. Menninger and B. Lang. 1997. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br. J. Rheumatol. 36:1298.
6. Miltenburg A.M.M., J.M. Van Laar, R. de Kuiper, M.R. Daha and F.C. Breedveld. Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid intcrleukin-6 levels with clinical and laboratory parameters of inflammation. Br. J. Rheumatol. 30:186.
7. Leeuwen M.A., J. Westra, P.C. Limburg P C, P.L.C.M. Riel and M.H. Rijswijk. 1995. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann. Rheum. Dis. 54:674.
8. Barrera P., C.J. Haagsma, A.M.T.H. Boerbooms, P.L.C.M. Riel, G.F. Borm, L.B.A. Putte, J.W.M. Meer. 1995. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br. J. Rheumatol. 34:747.
9. Barrera P., A.M.T.H. Boerbooms, P.N.M. Demacker, L.B.A. Putte, H. Gallati, J.W.M. Van der Meer. 1994. Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br. J. Rheumatol. 33:1017.
10. Littman B.H., C.E. Drury, R.O. Zimmerer, C.B. Stack and G.C. Law. 1995. Rheumatoid arthritis treated with tenidap and piroxicam. Clinical associations with cytokine modulation by tenidap. Arthritis Rheum. 38:29.
11. Kremer J.M. 1995. Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Br. J. Rheumatol. 34(suppl. 2):26.
12. Furst D.E. 1997. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br. J. Rheumatol. 36:1196.
13. Rau R., G. Herborn, H. Menninger and J. Blechschmidt. 1997. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br. J. Rheumatol. 36:345.
14. Haagsma C.J., P.L.C..M. Van Riel, A.J.L. De Jong, and L.B.A. Van De Putte. 1997. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br. J. Rheumatol. 36:1082.
15. Thomas R. and G.J. Carroll. 1993. Reduction of leukocyte and interleukin 1(concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 36:1244.
16. Snyder D.S. and E.R. Unanue. 1982. Corticosteroids inhibit murine macrophage Ia expression and interleukin-1 production. J. Immunol. 129:1803.
17. Schleimer R.P. 1990. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am. Rev. Respir. Dis. 141:S59.
18. Ropes M.W., G.A. Bennett, S. Cobb, R. Jacox and R.A. Jessar. 1958. Revision of diagnostic criteria forrheumatoid arthritis. Bull. Rheum. Dis. 9:175.
19. Combe B., L. Edno, P. Lafforgue, C. Bologna, J.C. Bernard, P. Acquaviva, J. Sany and F. Bressolle. 1995. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br. J. Rheumatol. 34:421.
20. Nowak D., M. Zieba, D. Zawiasa, J. Roz̀niecki and M. Król. 1996. Changes of serum concentration of lipid peroxidation products in patients with pneumonia. Monaldi Arch. Chest. Dis. 51:188.
21. Crilly A., I.E. McInness, A.G. McDonald, J. Watson, H.A. Capell and R. Madhok. 1995. Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J. Rheumatol. 22:224.
22. Danis V.A., G.M. Franic, D.A. Rathjen, D.M. Laurent and P.M. Brooks. 1992. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann. Rheum. Dis. 51:946.
23. Seitz M., P. Loetscher, B. Dewald, H. Towbin, C. Rordorf, H. Gallati, M. Baggiolini and N.J. Gerber. 1995. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br. J. Rheumatol. 34:602.
24. Chang D.M., M.E. Weinblatt and P.H. Shur. 1992. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J. Rheumatol. 19:1678.
25. Elliott M.J. and R.N. Maini. 1995. Anti-cytokine therapy in rheumatoid arthritis. Bailliere's Clin. Rheumatol. 9:633.
26. Guerne P.A., B.L. Zuraw, J.H. Vaughan, D.A. Carson and M. Lotz. 1989. Synovium as a source of interleukin 6 in vitro. J. Clin. Invest. 83:585.
27. Dinarello C.A. 1991. Interleukin-1 and interleukin-1 antagonism. Blood 77:1627.
28. Janero D.R. 1990. Malondialdehyde and thiobarbituric acid - reactivity as diagnostic indicies of lipid peroxidation and peroxidative tissue injury. Free Radical Biol. Med. 9:515.
29. Sikora A. 1995. The chemiluminescence assessment of peripheral blood polymorphonuclear leukocytes metabolic activity in juvenile chronic arthritis. Pol. J. Immunol. 20:97.